Business Description
GH Research PLC
NAICS : 541714
SIC : 2834
ISIN : IE000GID8VI0
Description
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders. The company is focused on developing novel and proprietary Mebufotenin 5-Methoxy-N, N-Dimethyltryptamine, or 5-MeO-DMT, therapies for the treatment of patients with Treatment-Resistant Depression, or TRD.
Financial Strength
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 175.98 | |||||
Equity-to-Asset | 0.96 | |||||
Debt-to-EBITDA | -0.03 | |||||
Piotroski F-Score | 1/9 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | -256 | |||||
3-Year EPS without NRI Growth Rate | -247.6 | |||||
3-Year FCF Growth Rate | -277 | |||||
3-Year Book Growth Rate | 231.1 | |||||
Future 3-5Y EPS without NRI Growth Rate | -27.14 |
Momentum Rank
3/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 50.02 | |||||
9-Day RSI | 47.69 | |||||
14-Day RSI | 47.76 | |||||
6-1 Month Momentum % | 175.51 | |||||
12-1 Month Momentum % | 13.45 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 22.06 | |||||
Quick Ratio | 22.06 | |||||
Cash Ratio | 21.7 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -2.1 | |||||
Shareholder Yield % | 0.03 |
Profitability Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
ROE % | -14.31 | |||||
ROA % | -13.86 | |||||
ROIC % | -58.23 | |||||
ROC (Joel Greenblatt) % | -2892.64 | |||||
ROCE % | -14.09 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PB Ratio | 2.91 | |||||
Price-to-Tangible-Book | 2.92 | |||||
EV-to-EBIT | -14.23 | |||||
EV-to-EBITDA | -14.37 | |||||
EV-to-Forward-EBITDA | -9.86 | |||||
EV-to-FCF | -12.57 | |||||
Price-to-Net-Current-Asset-Value | 4.01 | |||||
Price-to-Net-Cash | 4.07 | |||||
Earnings Yield (Greenblatt) % | -7.03 | |||||
FCF Yield % | -5.91 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
GH Research PLC Executives
DetailsGF Value
Analyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil €) | |||
EPS (TTM) (€) | -0.572 | ||
Beta | 0.64 | ||
Volatility % | 79.74 | ||
14-Day RSI | 47.76 | ||
14-Day ATR (€) | 0.311471 | ||
20-Day SMA (€) | 11.04 | ||
12-1 Month Momentum % | 13.45 | ||
52-Week Range (€) | 4.7 - 13.5 | ||
Shares Outstanding (Mil) | 52.03 |
Piotroski F-Score Details
Year:
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 1 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
GH Research PLC Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
GH Research PLC Stock Events
Event | Date | Price(€) | ||
---|---|---|---|---|
No Event Data |
GH Research PLC Frequently Asked Questions
What is GH Research PLC(FRA:1KA)'s stock price today?
The current price of FRA:1KA is €11.00. The 52 week high of FRA:1KA is €13.50 and 52 week low is €4.70.
When is next earnings date of GH Research PLC(FRA:1KA)?
The next earnings date of GH Research PLC(FRA:1KA) is 2024-08-23 Est..
Does GH Research PLC(FRA:1KA) pay dividends? If so, how much?
GH Research PLC(FRA:1KA) does not pay dividend.
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |